Hengrui Pharma(SH:600276) GLP1减重宝典·2025-12-06 11:31Core Viewpoint - Heng Rui Pharmaceutical is actively enhancing its international management team by recruiting senior talents from global pharmaceutical companies, aiming to strengthen its capabilities in the global innovative drug competition landscape [4][9]. Group 1: Leadership Changes - On December 3, Heng Rui announced the appointment of Zhu Guoxin as Senior Vice President, marking another significant step in the company's strategy to attract senior talent from multinational pharmaceutical firms [4]. - Zhu Guoxin has over 30 years of experience in global drug research and development, with expertise spanning various therapeutic areas including diabetes, obesity, and oncology [6]. - Prior to joining Heng Rui, Zhu held a Vice President position at Eli Lilly, overseeing multiple discovery and early development projects [6]. Group 2: Recent Executive Appointments - In September, Heng Rui appointed Hu Xinhui as Vice President and Chief Technology Officer, who has extensive experience in global technology and commercialization from companies like GSK and Merck [8]. - Sun Zhigang joined as Vice President and Chief Quality Officer from Green Leaf Pharmaceutical Group [8]. - Feng Ji was appointed as General Manager and Chief Operating Officer, bringing over 20 years of experience from AstraZeneca [8]. Group 3: Strategic Implications - The recent appointments reflect Heng Rui's strategy to accelerate the internationalization of its management team, enhancing its capabilities in research, production, quality, and commercialization [9]. - The influx of talent from leading pharmaceutical companies indicates a commitment to improving operational efficiency and strategic management within Heng Rui [9].